IMPERIAL Innovations yesterday said its portfolio company Cell Medica had begun commercial cell therapy manufacturing in Germany.
Shares in the Aim-listed commercialisation firm founded by Imperial College London rose as much as 3.3 per cent in early trading yesterday following the news.
“Cell Medica is one of the very first companies of its type to have taken a product from early development into commercial sales with an industrial-scale manufacturing system, which underlines Cell Medica’s position as one of the leaders in this new field of cell therapy,” said Imperial’s director of Healthcare Investments Maina Bhaman. “Cell Medica will now be able to leverage this manufacturing capability across a broad range of T-cell immunotherapy products, including both infectious disease and its exciting oncology programme.”
In November, Imperial led a £50m funding round in Cell leaving it with a 27.9 per cent stake in the group.